Allarity Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Allarity Therapeutics, Inc. (ALLR) reported Increase (Decrease) in Accrued Liabilities of -$696.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$220.00K.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$476.00K.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$53.00K, a 101.45% decline year-over-year.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$324.00K.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.70M, a 176.33% decline from fiscal 2024.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $3.54M, a 8123.26% increase from fiscal 2023.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $43.00K.
- Allarity Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$4.72M, a 165.61% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$220.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$696.00K 10-Q · filed 2026-08-14 | -$749.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.07M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$476.00K 10-Q · filed 2026-05-15 | -$529.00K derived: sum of 2 quarters · filed 2026-05-15 | -$853.00K derived: sum of 3 quarters · filed 2026-05-15 | -$3.17M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$377.00K derived: sum of 2 quarters · filed 2026-03-30 | -$2.70M derived: sum of 3 quarters · filed 2026-08-14 | -$2.70M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.64M derived: sum of 2 quarters · filed 2026-08-14 | -$2.65M 10-Q · filed 2025-11-14 | $1.01M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.32M 10-Q · filed 2026-08-14 | $1.34M derived: sum of 3 quarters · filed 2026-08-14 | $1.05M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$2.00K 10-Q · filed 2026-05-15 | $3.66M derived: sum of 2 quarters · filed 2026-05-15 | $3.38M derived: sum of 3 quarters · filed 2026-05-15 | $3.29M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.38M derived: sum of 2 quarters · filed 2026-03-30 | $3.29M derived: sum of 3 quarters · filed 2026-03-30 | $3.54M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$366.00K derived: sum of 2 quarters · filed 2025-11-14 | -$123.00K 10-Q · filed 2025-11-14 | $72.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $159.00K 10-Q · filed 2025-08-15 | $354.00K derived: sum of 3 quarters · filed 2025-08-15 | -$80.00K derived: sum of 4 quarters · filed 2025-08-15 | ||
| 2024-03-31 | $243.00K 10-Q · filed 2025-05-09 | $244.00K 10-Q · filed 2024-05-14 | $438.00K derived: sum of 2 quarters · filed 2025-05-09 | $4.00K derived: sum of 3 quarters · filed 2025-05-09 | -$148.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$239.00K derived: sum of 2 quarters · filed 2025-03-31 | -$391.00K derived: sum of 3 quarters · filed 2025-03-31 | $43.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$586.00K derived: sum of 2 quarters · filed 2024-11-14 | -$152.00K 10-Q · filed 2024-11-14 | -$88.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $282.00K 10-Q · filed 2024-08-05 | $346.00K derived: sum of 3 quarters · filed 2024-08-05 | $1.38M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $434.00K 10-Q · filed 2024-05-14 | $498.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.53M derived: sum of 3 quarters · filed 2024-05-14 | $2.02M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.10M derived: sum of 2 quarters · filed 2024-03-08 | $1.59M derived: sum of 3 quarters · filed 2024-03-08 | -$4.72M 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.52M derived: sum of 2 quarters · filed 2023-11-14 | -$4.79M 10-Q · filed 2023-11-14 | $1.30M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $488.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$5.82M 10-Q · filed 2023-08-14 | $270.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.30M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$6.31M 10-Q · filed 2023-05-11 | -$218.00K derived: sum of 2 quarters · filed 2023-05-11 | $813.00K derived: sum of 3 quarters · filed 2023-05-11 | $921.00K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $7.12M derived: sum of 2 quarters · filed 2023-03-13 | $7.23M derived: sum of 3 quarters · filed 2023-03-13 | $7.20M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.14M derived: sum of 2 quarters · filed 2022-11-14 | $1.11M 10-Q · filed 2022-11-14 | $1.06M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $76.00K 10-Q · filed 2022-10-07 | $33.00K derived: sum of 3 quarters · filed 2022-10-07 | |||
| 2021-03-31 | -$32.00K 10-Q · filed 2022-05-27 | -$75.00K derived: sum of 2 quarters · filed 2022-05-27 | ||||
| 2020-12-31 | -$43.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | -$36.00K 10-K · filed 2022-05-17 | ||||
| 2020-09-30 | $7.00K 10-Q/A · filed 2022-05-17 | $6.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |